Singapore’s Dx Assay Pushing Fee-for-service Model In Companion Diagnostics
This article was originally published in PharmAsia News
Executive Summary
Dx assays Pte. Ltd. says its fee-for-service business model makes it a unique provider of companion diagnostics in a market set to boom globally as U.S. FDA and other regulators push for drug firms to develop diagnostics alongside drugs.